E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Tubulin Inhibitors"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 October 2019

Special Issue Editor

Guest Editor
Prof. Dr. Romano Silvestri

Department of Drug Chemistry and Technologies, Universita degli Studi di Roma La Sapienza, Rome, Italy
Website | E-Mail
Interests: drug design and synthesis of new biologically active chemical entities in the areas of antitumor; antiviral or SNC drugs; the drug design is based on molecular models performed by either the internal unit or external research groups; new procedures for the microwave-assisted synthesis and the highly automated purification of relevant pharmaceutical molecules

Special Issue Information

Dear Colleagues,

Microtubule (MTs) play a key role in the division and motility of cells, manage the intracellular trafficking and preserve cell shape. The mitotic spindle generated by the MTs segregate the chromosomes during the cell division.  Both inhibition of tubulin polymerization and stabilization of disassembly alter the MT dynamic equilibrium, and, ultimately, cause lethal injury to the cell. Interfering with the MT dynamic equilibrium has drawn attention as a fruitful strategy to develop anticancer agents. A high proportion of cells treated with a MT targeting agent appear to be arrested in mitosis, show condensed chromosomes, lack of nuclear membrane and have damaged or no mitotic spindle. Over the past decades, an ever-growing number of compounds that bind to tubulin a,b-dimers, oligomers or polymers have been reported. The interference by these agents to the cell division has led the development of a wide variety of potential anticancer agents.

This Special Issue aims to attract contributions on all aspects of the chemistry and biological activity of tubulin binding agents. There's an unmet need for improved anticancer therapies. An exploration through tubulin binding agents and their biological effects may have a great impact on the advance of successful anticancer therapies.

Prof. Dr. Romano Silvestri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Tubulin
  • Microtubules
  • Interaction
  • Cancer
  • Chemotherapeutics

Published Papers

This special issue is now open for submission.
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top